Combination Therapies for Treating Cancer
AssigneesAscentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited, Guangzhou Healthquest Pharma Co., Ltd.
InventorsYifan ZHAI, Dajun YANG, Guangfeng WANG, Miaozhen QIU, Fan LUO
Life of this patent
Estimating the term…
Abstract
The present invention relates to one or more combination treatments of cancer patients with a compound of formula (I), and an allosteric inhibitor or an immune checkpoint molecule, wherein R1 and R2 are as described herein.
Claims28
A method of treating cancer comprising co-administering to a subject in need thereof:
- a) a compound of formula (I) or a pharmaceutically acceptable salt thereof;
- and
- b) an allosteric inhibitor;
- wherein formula (I) has the following structure:
- wherein
- R1 is hydrogen, C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkyloxy, or phenyl;
- and
- R2 is hydrogen, C1-4 alkyl, C3-6 cycloalkyl, or halogen;
- wherein the cancer is hematological malignancy.
-4. (canceled)
-13. (canceled)
A method of inhibiting BCR-ABL mutants comprising contacting BCR-ABL mutants with a) HQP-1351 or a pharmaceutically acceptable salt thereof;
- and b) asciminib;
- wherein HQP-1351 has the following structure:
-16. (canceled)
A method of treating cancer comprising co-administering to a subject in need thereof:
- a) HQP-1351 or a pharmaceutically acceptable salt thereof;
- and
- b) an immune checkpoint molecule selected from PD-1, PD-L1, PD-L2, CTLA-4, TIM-3, LAG3, CD160, 2B4, TGFβ, VISTA, BTLA, TIGIT and LAIR1;
- wherein the cancer is breast cancer, cervical cancer, ovarian cancer, endometrial cancer, prostate cancer, colon cancer, bladder cancer, bone metastasis, colorectal cancer, esophagus cancer, head and neck cancer, small cell lung cancer, non-small cell lung carcinoid tumor, or stomach carcinoma, wherein HQP-1351 has the following structure:
-25. (canceled)
28-37. (canceled)
A method of inhibiting proliferation of Ph+ ALL SUP-B15 cells or inducing apoptosis of primary pre-B ALL cells and ALL cells comprising administering to a subject in need thereof HQP-1351 or a pharmaceutically acceptable salt thereof, wherein HQP-1351 has the following structure:
(canceled)
A method of treating renal cancer comprising co-administering to a subject in need thereof:
- a) HQP-1351 or a pharmaceutically acceptable salt thereof;
- and
- b) an anti-PD-1 antibody selected from InVivoMab anti-mouse PD-1(CD279), wherein HQP-1351 has the following structure:
-42. (canceled)
-47. (canceled)
Dependencies are inferred from the claim text.